(Q34699444)

4 August 2017

title

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro (English)

1 reference

4 August 2017

Malin Wickström

1

0 references

Rolf Larsson

series ordinal

5

object named as

Rolf Larsson

1 reference

4 August 2017

4

Peter Nygren

1 reference

4 August 2017

6

Joachim Gullbo

1 reference

4 August 2017

2

Caroline Haglund

1 reference

4 August 2017

Henrik Lindman

3

1 reference

4 August 2017

publication date

6 October 2007

1 reference

Investigational New Drugs

4 August 2017

published in

1 reference

4 August 2017

volume

26

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

195-204

1 reference

High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer

4 August 2017

cites work

1 reference

12 December 2020

Peptichemio versus melphalan (L-PAM) in advanced breast cancer

1 reference

12 December 2020

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation

1 reference

12 December 2020

Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma

1 reference

12 December 2020

Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia

1 reference

12 December 2020

Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo

1 reference

12 December 2020

Gene expression in colorectal cancer

1 reference

12 December 2020

Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.

1 reference

12 December 2020

Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma

1 reference

12 December 2020

Clinical significance of aminopeptidase N in non-small cell lung cancer

1 reference

12 December 2020

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

12 December 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

12 December 2020

L-phenylalanine mustard (L-PAM): the first 25 years

1 reference

12 December 2020

Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer

1 reference

12 December 2020

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).

1 reference

12 December 2020

Expression of aminopeptidase N/CD13 in human ovarian cancers

1 reference

12 December 2020

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

1 reference

12 December 2020

Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia

1 reference

12 December 2020

Decreases of metallothionein and aminopeptidase N in renal cancer tissues

1 reference

12 December 2020

Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic

1 reference

12 December 2020

Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan

1 reference

12 December 2020

Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells.

1 reference

12 December 2020

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo

1 reference

12 December 2020

Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid

1 reference

12 December 2020

Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancer.

1 reference

12 December 2020

Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma

1 reference

12 December 2020

Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.

1 reference

12 December 2020

Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.

1 reference

12 December 2020

Screening of an annotated compound library for drug activity in a resistant myeloma cell line

1 reference

12 December 2020

Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)

1 reference

12 December 2020

Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin

1 reference

12 December 2020

Aminopeptidase activities in breast cancer tissue

1 reference

12 December 2020

A monoclonal antibody driven biodiagnostic system for the quantitative screening of breast cancer

1 reference

12 December 2020

Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor

1 reference

12 December 2020

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

1 reference

12 December 2020

10.1007/S10637-007-9092-1

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1011744604

0 references

1 reference